IL10 and lung carcinoma: The research by Vahl and colleagues showed that IL-10 competes with IFN-γ on the PD1/PDL1 pathway, potentially contributing to resistance to PD1/PDL1 immunotherapy in lung cancer patients (Vahl et al., 2017).